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Phosphatidylinositol-3-kinase (PI3K) is acti-
vated  downstream  of  numerous  receptors   
and catalyzes the conversion of membrane 
phosphatidylinositol-(4,5)-bisphosphate (PI4,5P2) 
to phosphatidylinositol-(3,4,5)-trisphosphate 
(PIP3). PIP3 acts as a second messenger, re-
cruiting to the plasma membrane pleckstrin 
homology domain–containing adaptors and 
kinases such as PDK1, Akt, PLC-, Tec family 
kinases, and DOK, which then further mod-
ulate downstream signaling (Cully et al., 2006). 
Subsequent activation or inactivation of cy-
tosolic  and  nuclear  targets,  including  SGK, 
mTOR, PP2A, FOXO, and cyclins D and E, 
mediates  diverse  cellular  responses  such  as 
survival, proliferation, migration, adhesion, and 
differentiation (Cully et al., 2006). In B cells, 
attenuated PI3K signaling impairs B cell sur-
vival  and  selection,  leading  to  diminished 
numbers of peritoneal B-1 cells, splenic mar-
ginal zone (MZ) B cells, and germinal center 
(GC) B cells, as well as a general reduction in 
mature  recirculating  B  cells  (Donahue  and 
Fruman, 2004).
The action of PI3K is antagonized by two 
lipid phosphatases: the 3-inositol phosphatase, 
phosphatase and tensin homologue (PTEN), and 
the 5-inositol phosphatase Src homology 2 (SH2) 
domain–containing inositol phosphatase (SHIP). 
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The inositol phosphatases phosphatase and tensin homologue (PTEN) and Src homology 2  
domain–containing inositol phosphatase (SHIP) negatively regulate phosphatidylinositol-3-kinase 
(PI3K)–mediated growth, survival, and proliferation of hematopoietic cells. Although deletion of 
PTEN in mouse T cells results in lethal T cell lymphomas, we find that animals lacking PTEN or 
SHIP in B cells show no evidence of malignancy. However, concomitant deletion of PTEN and 
SHIP (bPTEN/SHIP/) results in spontaneous and lethal mature B cell neoplasms consistent with 
marginal zone lymphoma or, less frequently, follicular or centroblastic lymphoma. bPTEN/SHIP/ 
B cells exhibit enhanced survival and express more MCL1 and less Bim. These cells also express 
low amounts of p27kip1 and high amounts of cyclin D3 and thus appear poised to undergo prolif-
erative expansion. Unlike normal B cells, bPTEN/SHIP/ B cells proliferate to the prosurvival 
factor B cell activating factor (BAFF). Interestingly, although BAFF availability may promote 
lymphoma progression, we demonstrate that BAFF is not required for the expansion of trans-
ferred bPTEN/SHIP/ B cells. This study reveals that PTEN and SHIP act cooperatively to suppress 
B cell lymphoma and provides the first direct evidence that SHIP is a tumor suppressor. As such, 
assessment of both PTEN and SHIP function are relevant to understanding the etiology of human 
B cell malignancies that exhibit augmented activation of the PI3K pathway.
© 2010 Miletic et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e2408 PTEN and SHIP regulate B cell transformation | Miletic et al.
RESULTS
Deletion of Pten and Ship in B cells results in lethal disease 
characterized by splenomegaly, B cell expansion,  
and disrupted splenic architecture
Although deletion of Pten in mouse T cells results in lethal T cell 
lymphomas (Suzuki et al., 2001), animals lacking Pten in B cells 
(bPTEN/) show no evidence of malignancy (Anzelon et al., 
2003). Similarly, there are no reports of malignancies in mice 
lacking SHIP in B cells. To determine if PTEN and SHIP co-
ordinately suppress B cell transformation, we generated mice 
with a B cell–specific deletion of both Pten and Ship (bPTEN/
SHIP/) by mating bPTEN/ mice (Anzelon et al., 2003) 
with a novel strain of mice lacking SHIP only in B cells 
(bSHIP/; see Materials and methods; Fig. S1 A). As early as   
4 mo of age, bPTEN/SHIP/ (but not bPTEN/, bSHIP/, 
or bPTEN/SHIP+/) mice exhibited lethargy, weight loss   
(Fig. 1 A), hunched posture, ruffled fur, and splenomegaly   
(Fig. 1, A and B). Severe morbidity and death occurred in all 
bPTEN/SHIP/ animals by 1 yr of age (Fig. 1 C and not de-
picted). In contrast, WT, bPTEN/, and bSHIP/ controls 
did not develop splenomegaly and failed to display any signs of 
disease noted in bPTEN/SHIP/ mice (Fig. 1, B and C). As 
compared with spleens of control animals, spleens of aged   
bPTEN/SHIP/ mice (>6 mo of age) displayed an expansion 
of CD19+ B cells, resulting in enlarged white pulp areas that 
often infiltrated and compressed the red pulp (Fig. 1, D and E; 
and not depicted). Notably, tissues containing the expanded   
B cell population also displayed an expansion of CD11b+ my-
eloid cells (Fig. 1 E and not depicted). Concurrent with disease 
onset, bPTEN/SHIP/ B cells and myeloid cells were found 
in liver and lung and, less frequently, kidney infiltrates and often 
formed visible masses in nonlymphoid tissues (Fig. 1 F). Thus, 
unlike loss of either PTEN or SHIP alone, loss of both PTEN 
and SHIP in B cells results in an aggressive and fatal disease as-
sociated with immune cell expansion.
bPTEN/SHIP/ B cells acquire a surface phenotype 
consistent with B cell lymphoma
To  determine  whether  the  disease  observed  in  bPTEN/
SHIP/  mice  represents  a  lymphoproliferative  disease  or  a 
neoplastic disorder, we examined the phenotypes of peripheral 
B cells in WT, bPTEN/, bSHIP/, and bPTEN/SHIP/ 
animals. Flow cytometric analyses of peripheral blood lympho-
cytes (PBL) showed a reduction in the frequency of B cells in 
asymptomatic bPTEN/SHIP/ mice (Fig. 2 A, pre, ≤6 mo) as 
compared with WT, bPTEN/, or bSHIP/ mice (Fig. 2 A), 
perhaps as a result of retention of B cells in the lymphoid tissues. 
bPTEN/SHIP/ animals older than 6 mo had a threefold in-
crease in the percentage of recirculating B cells in the blood, 
concurrent with the onset of disease (Fig. 2 A). Notably, the per-
centage of CD19+ B cells in bPTEN/SHIP/ animals was 
comparable to that of WT, bPTEN/, and bSHIP/ mice, 
even in the blood of diseased bPTEN/SHIP/ mice (Fig. 2 B). 
However, in the latter group, the associated severe splenomegaly 
likely indicates a parallel expansion or recruitment of non–B cells 
into the spleen. Moreover, although diseased bPTEN/SHIP/ 
Although  both  PTEN  and  SHIP  hydrolyze  PIP3,  the   
generation  of  their  distinct  lipid  products,  PI4,5P2  and 
PI3,4P2, respectively, likely confers specificity in effector re-
cruitment to the plasma membrane. PTEN is a ubiqui-
tously expressed and highly active enzyme that regulates 
basal  and  induced  PIP3  levels  via  dynamic  interactions 
with the plasma membrane (Vazquez and Devreotes, 2006). 
In contrast, plasma membrane recruitment of hematopoi-
etically restricted SHIP requires binding of its SH2 do-
main to proteins bearing specific phosphotyrosine motifs 
(Rohrschneider et al., 2000). In B cells, SHIP is recruited 
to the negative regulatory Fc receptor II-B, where it reg-
ulates  signals  induced  by  immune-complexed  antigen. 
SHIP also attenuates autonomous B cell receptor (BCR) 
signaling via an unknown mechanism (Brauweiler et al., 
2000b). The restricted versus expansive roles of SHIP and 
PTEN,  respectively,  are  supported  by  in  vivo  studies  of 
mice  lacking  SHIP  and  PTEN,  individually,  in  B  cells.   
In SHIP/ mice, the peripheral B cell compartment is re-
duced  whereas  BCR-induced  proliferation  is  enhanced 
(Liu et al., 1998; Brauweiler et al., 2000a; Helgason et al., 
2000). PTEN-deficient B cells exhibit preferential differ-
entiation into MZ or B-1 B cells and are hyperresponsive 
to extracellular stimuli (Anzelon et al., 2003; Suzuki et al., 
2003). PTEN is the second most frequently mutated gene 
documented in human cancers (after the tumor suppressor 
TP53), and activation of the PI3K signaling pathway has 
been implicated in B cell neoplasia (Barragán et al., 2002; 
Cuní et al., 2004; Smith et al., 2005; Rudelius et al., 2006; 
Uddin et al., 2006). Nonetheless, PTEN gene mutations 
are surprisingly infrequent in human B cell malignancies 
(Sakai et al., 1998; Butler et al., 1999). Furthermore, al-
though conditional deletion of Pten in mouse T lympho-
cytes leads to lethal T cell lymphomas, inactivation of Pten 
in B cells is not a transforming event (Suzuki et al., 2001, 
2003; Anzelon et al., 2003). Thus, we hypothesized that the 
potential  for  PI3K-dependent  B  cell  transformation  re-
mains suppressed in the absence of PTEN as a result of the 
activity of SHIP.
In this paper, we provide strong support for this hy-
pothesis, showing that mice lacking expression of PTEN 
and SHIP in B cells (bPTEN/SHIP/) develop lethal B 
cell lymphomas with similarities to human mature B cell 
lymphomas.  bPTEN/SHIP/  B  cells  exhibit  enhanced 
PI3K signaling downstream of both BCR and cytokine 
receptors and an acquired mitogenic response to the sur-
vival factor B cell activating factor (BAFF). Analysis of cell 
cycle regulators suggests that the BCR and BAFF-R syn-
ergize to promote lymphoma progression. Together, these 
data represent the first demonstration of SHIP as a tumor 
suppressor. As such, assessment of both PTEN and SHIP 
function is relevant to understanding the etiology of B cell 
malignancies, such as diffuse large B cell lymphoma (DL-
BCL) and mantle cell lymphoma (MCL), which present 
augmented  activation  of  the  PI3K  pathway  (Rudelius   
et al., 2006; Uddin et al., 2006).JEM VOL. 207, October 25, 2010 
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bPTEN/SHIP/ mice shared an altered yet uniform pheno-
type, suggesting that bPTEN/SHIP/ B cells found in non-
lymphoid organs had metastasized from secondary lymphoid 
tissues (Fig. 2 C). The phenotype of bPTEN/SHIP/  
B cells was similar to that of B1a B cells that predominate in 
the peritoneal and pleural cavities of WT mice (Hardy et al., 
2006) but was quite distinct from that of normal follicular, 
MZ, GC, or memory B cells. Importantly, however, most 
documented mouse B cell lymphomas, whether derived from 
MZ or GC B cells, are CD5low, and a significant proportion 
also express CD11b (Fig. 2 C; Morse et al., 2002). Collec-
tively, the surface phenotype and increased size of bPTEN/
SHIP/ B cells is consistent with B cell neoplasia.
PTEN/SHIP/ B cells are oligoclonal and transfer disease
The majority of histologically defined mouse lymphomas are 
monoclonal or oligoclonal, as demonstrated by Southern blot 
mice had hematocrits and hemoglobin values comparable to 
those of age-matched WT controls, peripheral blood smears   
revealed lymphocytes that resembled lymphoma cells based on 
cell size and nuclear features (unpublished data).
Flow cytometric analyses of recirculating CD19+ bPTEN/
SHIP/ B cells showed that they were larger than B cells   
from WT, bPTEN/, or bSHIP/ mice, as indicated by   
forward light scatter (Fig. 2 C). bPTEN/SHIP/ B cells were 
predominantly  B220low/IgM+/lowIgDCD11b+CD5+/low 
CD43+CD21/lowCD23 (Fig. 2, B and C) but did not ex-
press markers characteristic of T cells (CD3, CD4, and CD8) 
or markers of dendritic cells (CD11c), granulocytes (Gr1), or 
macrophages/myeloid cells (F4/80; not depicted). In asymp-
tomatic prelymphoma mice, splenic B cells exhibited bimodal 
expression of some markers, indicating the presence of nor-
mal and altered B cell populations (Fig. 2 C). By comparison, 
splenic B cells and B cells present in liver masses of diseased 
Figure 1.  bPTEN/SHIP/ mice develop a lethal disease characterized by weight loss, splenomegaly, and altered splenic architecture.  
(A) Spleen (left axis) and body (right axis) weight (grams) of WT (black bar) and bPTEN/SHIP/ (white bar) mice between 7 and 12 mo of age (n = 7).  
Error bars represent SD of spleen and body weights of WT or bPTEN/SHIP/ mice shown. (B) Representative photograph of spleens from WT (12 mo), 
bPTEN/ (12 mo), bSHIP/ (12 mo), and bPTEN/SHIP/ (8 mo) mice. Image is representative of n > 25 mice of each genotype. (C) Survival of WT (n = 20), 
bPTEN/ (n = 15), bSHIP/ (n = 15), and bPTEN/SHIP/ (n = 20) mice monitored for 1 yr. (D) Hemotoxylin/eosin (H&E) staining of microsections from 
paraffin-embedded spleens. The age of mice shown was 4 or 10 mo, as indicated. Pictures are representative of >40 mice of each genotype. Magnification 
shown is with a 5× objective. Bars, 500 µm. (E) Immunofluorescence of spleens of WT and bPTEN/SHIP/ mice of indicated ages stained with -CD19-PE 
(red), -CD11b-FITC (green), and F4/80-APC (blue). Magnification shown is 5×. Bars, 500 µm. (F) H&E-stained sections from paraffin-embedded liver (top) 
and lung (bottom) of WT and bPTEN/SHIP/ mice. Arrows indicate white blood cell infiltrates. Results are representative of >20 WT and bPTEN/SHIP/ 
mice >6 mo of age. Magnification shown is with a 5× objective (first and third rows) or 40× objective (second and fourth rows). Scale bars: (5×) 500 µm; 
(40×) 100 µm.2410 PTEN and SHIP regulate B cell transformation | Miletic et al.
the same clones had disseminated from lymphoid to nonlym-
phoid organs in diseased bPTEN/SHIP/ mice (Fig. 3 B).
Mouse B lymphoma cells differ from untransformed WT 
B cells in their capacity to expand and propagate disease after 
transfer into immunocompromised hosts. To determine if   
bPTEN/SHIP/ B cells would transfer disease, WT or   
bPTEN/SHIP/ B cells were transferred intravenously into 
T cell–deficient (TCR-/) recipients, and the presence of 
transferred cells was monitored in peripheral blood at regular 
intervals. Consistent with their designation as transformed 
cells, bPTEN/SHIP/ B cells expanded after adoptive trans-
fer into TCR-/ recipients, whereas WT B cells failed to 
persist (Fig. 4, A and B).
By 3 mo after transfer, CD19+B220lowCD5+CD11b+ B cells 
represented 60–70% of peripheral blood B cells in recipients 
that received bPTEN/SHIP/ B cells (Fig. 4, B and C).   
In contrast, WT B cells neither survived nor expanded after 
transfer (Fig. 4, B and C). Examination of IgH usage in B cells 
analysis of Ig heavy chain (IgH) J gene organization or by PCR 
analysis of IgH V gene usage (Morse et al., 2002). Thus, to further 
distinguish between neoplastic and lymphoproliferative disease, 
genomic DNA from splenic B cells of age-matched WT and 
bPTEN/SHIP/ mice was analyzed by Southern blotting for 
clonal rearrangements at the IgH locus using the JH-specific 
probe pJ11 (Stall et al., 1988). Numerous JH rearrangements were 
detected in genomic DNA from B cells of WT and asymptom-
atic (prelymphoma) bPTEN/SHIP/ mice (Fig. 3 A), indicative 
of a polyclonal B cell pool. In striking contrast, distinct non-
germline bands were identified in DNA from several diseased 
(lymphoma) bPTEN/SHIP/ mice, revealing the presence of 
clonal B cell outgrowths (Fig. 3 A). PCR analyses using VH1- 
and VH5-specific 5 and shared 3 JH primers were used to deter-
mine if B cells present in nonlymphoid tissues and spleen were 
of common origin in individual mice (Fig. 3 B). In several cases, 
the same dominant rearrangement was observed in B cells iso-
lated from several tissues within the same animal, indicating that 
Figure 2.  bPTEN/SHIP/ B cells display a surface phenotype consistent with B cell lymphoma. (A) Percentage of CD19+ leukocytes in peripheral 
blood (PBL) and spleen of indicated mice, as determined by flow cytometry. pre = prelymphoma; bPS = bPTEN/SHIP/. P-value was determined by two-
tailed Student’s t test. Error bars represent SD of percentages of CD19+ B cells in blood or spleens of mice shown. (B) Flow cytometric analysis of PBL or 
spleen comparing expression of CD19 versus CD5. Numbers above gates indicate the percentage of CD19+ B cells in PBL or spleen, as indicated. (C) Flow 
cytometric analysis of CD19+ cells in PBL or single cell suspensions of spleen (top) using antibodies against cell surface markers, as indicated. The bottom 
shows a comparison of liver metastases and spleen of a diseased bPTEN/SHIP/ mouse. All histograms show gated CD19+ cells. All flow cytometry data are 
representative of five independent age-matched cohorts. WT, n = 10; bPTEN/, n = 4; bSHIP/, n = 9; bPTEN/SHIP/ pre, n = 5; bPTEN/SHIP/, n = 6.JEM VOL. 207, October 25, 2010 
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bPTEN/SHIP/ mice, we first examined the in vitro prolif-
erative responses of B cells lacking PTEN and/or SHIP to 
BCR stimulation. Consistent with previous results, bPTEN/ 
and bSHIP/ B cells proliferated robustly upon ligation of 
the BCR with anti-IgM F(ab’)2 fragments (Helgason et al., 
2000; Anzelon et al., 2003; Suzuki et al., 2003). Intriguingly, 
however, bPTEN/SHIP/ B cells were less responsive than 
bPTEN/, bSHIP/, or WT B cells (Fig. 5 A). Notably, 
bPTEN/SHIP/ B cells were not generally refractory to 
proliferative stimuli, as they showed robust proliferative response 
to LPS or anti-CD40 that exceeded those of WT B cells and 
were comparable to those of bPTEN/ B cells (Fig. S3).   
Because the adoptive transfer studies indicated that T cells or 
T cell–derived factors were not required for lymphomagenesis, 
we considered a role for BAFF, as it is broadly available in vivo 
and critical for B cell survival (Mackay and Schneider, 2009). The 
addition of BAFF to anti-IgM–stimulated cells enhanced prolife-
ration in B cells from WT, bPTEN/, bSHIP/, and bPTEN/
SHIP/ mice (Fig. 5 A). Strikingly, treatment with BAFF 
alone induced proliferation of bPTEN/SHIP/ but not of WT, 
bPTEN/, or bSHIP/ B cells (Fig. 5 A). Proliferation of 
bPTEN/SHIP/ B cells to BAFF was unique, as treatment 
with  the  related  cytokine,  a  proliferation-inducing  ligand 
(APRIL), failed to induce a proliferative response (Fig. 5 A).
To examine how BCR ligation and BAFF stimulation 
promote cell cycle entry in bPTEN/SHIP/ B cells, expression 
levels of p27kip1 and cyclin D3 were examined. The inability 
transferred into TCR-/ recipients showed that all WT   
B cells (before and after transfer) showed a diverse polyclonal 
IgH repertoire (Fig. S2). Several TCR-/ recipient ani-
mals that received bPTEN/SHIP/ B cells showed expan-
sion of the same clones as the original transferred B cells, 
whereas others showed an expansion of unique clones that 
may not have been well represented in the original trans-
ferred  population  but  expanded  after  transfer  (Fig.  S2).   
Additionally, 2–5 mo after adoptive transfer, recipients of   
bPTEN/SHIP/ B cells exhibited signs of disease similar to 
those  observed  in  unmanipulated  bPTEN/SHIP/  mice 
(Fig. 4 D) and, at necropsy, were found to have extensive cellular 
infiltrations of lungs, livers, and other nonlymphoid tissues (not 
depicted). The combined evidence of cell surface phenotype, 
clonality, and ability to transfer disease indicates that bPTEN/
SHIP/ mice develop B cell neoplasia rather than a B cell 
proliferative disease.
BAFF is mitogenic for bPTEN/SHIP/ lymphoma cells
Similar to B cells from healthy mice, most explanted lym-
phoma cells generally do not replicate spontaneously ex vivo 
(despite the aggressive nature of most lymphomas in vivo), 
indicating that environmental stimuli are required for con-
tinued growth. In addition, however, mature B cells require 
tonic signaling via the BCR for maintenance and survival 
(Lam et al., 1997; Kraus et al., 2004). To understand which 
signals may contribute to the development of lymphomas in   
Figure 3.  bPTEN/SHIP/ B cells have oligoclonal Ig repertoires. (A) Rearrangements of the heavy chain of WT and bPTEN/SHIP/ B cells were 
detected using the pJ11 probe, which preferentially detects rearrangements to JH1, JH2, and JH3. All mice were >6 mo of age and B cells were isolated 
from spleen. Pre-lymph. = prelymphoma. Clonal rearrangements are indicated by ellipses. Each lane represents an individual mouse. (B) PCR analysis of Ig 
V-DJH recombination using degenerate 5 primers specific for either the distal J558 (VH1) or the proximal 7183 (VH5) family and a common 3 JH4 primer 
on DNA from spleen (sp), liver (li), and/or lung (lu) from WT or bPTEN/SHIP/ mice. Arrows indicate amplified V-DJH1, V-DJH2, and V-DJH3 segment  
recombinations (1.3, 0.95, and 0.4 kb, respectively). Representative samples are shown for WT and young (<6 mo) and old (>6 mo) bPTEN/SHIP/ mice.2412 PTEN and SHIP regulate B cell transformation | Miletic et al.
activity (Fig. 5 C). These data suggest a mechanism by which   
bPTEN/SHIP/ B cells are biochemically poised to proliferate 
after BAFF stimulation.
WT, bPTEN/, bSHIP/, and bPTEN/SHIP/ B cells 
were stimulated in vitro with anti-IgM in the presence or ab-
sence of BAFF. Compared with controls, bPTEN/SHIP/  
B cells consistently showed decreased expression of p27kip1 
and increased cyclin D3 expression under all stimulation con-
ditions (Fig. 5 B). Furthermore, signaling through the BCR in 
bPTEN/SHIP/ B cells in the presence or absence of BAFF 
also resulted in hyperactivation of Akt in bPTEN/SHIP/  
B cells (Fig. 5 C). Together, these data indicate that although 
of BAFF alone to induce proliferation of WT B cells results 
from a failure to down-regulate p27kip1 (Huang et al., 2004), a 
cyclin-dependent kinase inhibitor which is negatively regulated 
by Akt either directly or via inhibition of the FOXO factors. 
As compared with WT and single-deficient B cells, bPTEN/
SHIP/ B cells assayed directly ex vivo displayed diminished 
expression of p27kip1 as well as enhanced expression of cyclin D3, 
an indicator of entry into the G1 phase of the cell cycle   
(Fig. 5 B). Consistent with these results, activated Akt, indicated 
by phosphorylation at serine 473, was readily detected in un-
stimulated bPTEN/SHIP/ B cells. This is in contrast to WT 
and single knockout controls which failed to show basal Akt   
Figure 4.  bPTEN/SHIP/ B cells induce disease upon transfer into TCR-/ recipients. (A) bPTEN/SHIP/ or WT splenic B cells from age-
matched mice were transferred intravenously into TCR-/ recipients and donor cell accumulation in recipient peripheral blood assessed by flow cy-
tometry at the indicated weeks. Shown are CD19+-gated PBL from four representative animals. Two received bPTEN/SHIP/ B cells and two received WT 
B cells. The bPTEN/SHIP/ mouse shown in the top panel died before 12 wk. (n = 8 WT recipients and 9 bPTEN/SHIP/ recipients). (B) The percentage of 
CD5+CD19+B220low B cells in the peripheral blood of TCR-/ animals after adoptive transfer of WT or bPTEN/SHIP/ B cells is shown over time. Each 
point represents a single animal. Error bars represent SD of percentages of CD5+CD19+B220low PBLs in chimeric mice at each time point shown. (C) Flow 
cytometry plots of PBLs from representative chimeras stained for CD19, B220, CD11b, CD5, and IgD. Data shown are 9 wk after transfer. (D) Kaplan-Meier 
survival curve of TCR-/ recipients after adoptive transfer of WT or bPTEN/SHIP/ B cells. WT, n = 8; bPTEN/SHIP/, n = 9.JEM VOL. 207, October 25, 2010 
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not result in reduced viability of bPTEN/SHIP/ B cells as 
compared with untreated cells (Fig. S4 D). Thus, although 
BAFF provides a mitogenic signal to bPTEN/SHIP/ B cells, 
it is not an absolute requirement for lymphoma progression in 
situations in which PI3K signaling is deregulated.
bPTEN/SHIP/ B cells show enhanced survival
Mouse B cell lymphoma cells not only survive and expand 
after transfer into immunocompromised recipient animals but 
they also persist in vitro. Given the presence of activated Akt in 
freshly isolated bPTEN/SHIP/ B cells (Fig. 5 C), we pro-
ceeded to examine the survival of B cells lacking expression 
of PTEN and/or SHIP. Splenic B cells were purified from 
WT, bPTEN/, bSHIP/, and bPTEN/SHIP/ mice and 
cultured in the absence of mitogenic stimuli or survival factors. 
In contrast to their rapid in vivo expansion after transfer into 
TCR-/ hosts, bPTEN/SHIP/ lymphoma cells persisted 
bPTEN/SHIP/ B cells are biochemically hyperresponsive to 
signals through the BCR and BAFF receptors and up-regulate 
cyclin D3 in response to BCR stimulation, signals through the 
BCR and BAFF receptors alone are likely not sufficient to 
support their survival and expansion in vivo.
To directly assess the contribution of BAFF signaling to 
lymphoma progression, WT or bPTEN/SHIP/ B cells were 
transferred into sublethally irradiated BAFF/ animals and 
monitored over a 6-mo period for the appearance of lymphoma 
cells in the peripheral blood. As expected, WT B cells failed to 
survive and expand in the absence of BAFF in vivo (Fig. S4 A). 
However, we found that bPTEN/SHIP/ B cells were able 
to expand in some (4/11) BAFF/ recipients (Fig. S4 A). 
This result cannot be explained by autocrine production of 
BAFF, as BAFF message was not detectable by RT-PCR analysis 
of bPTEN/SHIP/ B cells (Fig. S4 B). Moreover, blockade 
of BAFF in in vitro cultures of bPTEN/SHIP/ B cells did 
Figure 5.  bPTEN/SHIP/ B cells proliferate in response to treatment with BAFF. (A) Purified splenic B cells from WT, bPTEN/, bSHIP/, or  
bPTEN/SHIP/ mice were stimulated with anti-IgM F(ab’)2 (-IgM) in the presence or absence of BAFF or with APRIL as indicated. Proliferation was deter-
mined at 48 h by 3H-thymidine incorporation. Y-axis values shown are ×103 cpm. All assays were conducted in triplicates and SDs are shown as error 
bars. The results are representative of six experiments. (B) Western blots of protein lysates from WT, bPTEN/ (P), bSHIP/ (S), or bPTEN/SHIP/ (PS) 
splenic B cells either freshly isolated (t = 0) or stimulated for 48 h, as indicated, were probed with anti-p27kip1, anti-cyclin D3, or anti-actin antibodies.  
(C) WT, bPTEN/, bSHIP/, or bPTEN/SHIP/ B cells were stimulated with anti-IgM F(ab’)2 (-IgM), BAFF, or anti-IgM F(ab’)2 (-IgM) + BAFF for the 
indicated time points. Western blots were probed with antibodies recognizing the phosphorylated form of Akt (Ser 473). Total ERK1/2 was used as a load-
ing control. For B and C, data are representative of n = 5 independent experiments.2414 PTEN and SHIP regulate B cell transformation | Miletic et al.
Consistent with inhibition of GSK by Akt and GSK3- 
dependent  degradation  of  the  prosurvival  factor  MCL1 
(Maurer et al., 2006), bPTEN/SHIP/ B cells expressed 
elevated amounts of MCL1 compared with WT, bPTEN/, 
or bSHIP/ B cells at all time points examined (Fig. 6 C). 
Moreover, freshly isolated bPTEN/SHIP/ B cells ex-
pressed lower levels of the pro-apoptotic factor and FOXO-
regulated gene product Bim (Dijkers et al., 2000) than WT 
or bSHIP/ controls (Fig. 6 D). Interestingly, bPTEN/  
B  cells  also  expressed  lower  levels  of  Bim  than WT  or 
bSHIP/ B cells but did not survive in vitro, suggesting 
that factors in addition to Bim may be responsible for the 
enhanced survival and expansion of bPTEN/SHIP/ B cells 
both in vivo and in vitro.
but did not proliferate when cultured in the absence of stimula-
tion ex vivo (Fig. 6 A). In contrast, B cells from WT and single 
mutant bPTEN/ and bSHIP/ mice did not persist and 
died more rapidly than bPTEN/SHIP/ B cells (Fig. 6 A). 
In this regard, bPTEN/SHIP/ B cell cultures contained an 
increased percentage of live cells as indicated by annexin V 
and propidium iodide staining compared with cultures of WT 
or single knockout B cells (Fig. 6 B). Consistent with increased 
survival and basally activated Akt (Fig. 6 C), levels of GSK3(S9) 
phosphorylation, corresponding to the negative regulatory 
site  for Akt,  were  also  augmented  in  bPTEN/SHIP/  
B cells (Fig. 6 C). Notably, phosphorylation of Akt and 
GSK3 in bPTEN/SHIP/ B cells was detected not only in 
freshly isolated B cells but also in cells from long-term culture.   
Figure 6.  bPTEN/SHIP/ B cells survive better than WT, bPTEN/, or bSHIP/ B cells in vitro. (A) WT, bPTEN/, bSHIP/, or bPTEN/SHIP/  
B cells were cultured at a starting concentration of 5 × 105 cells/ml in media lacking any growth factors and surviving cells were counted every 24 h  
using a Coulter counter. Data are representative of n = 3 independent experiments. Error bars represent SD of total live cells of triplicate wells counted  
in triplicate for each mouse. (B) As in A, with the modification that cell viability was assessed by annexin V (Ann V) and propidium iodide (PI) staining. 
(Top) Shown is a representative panel of WT, bPTEN/, bSHIP/, and bPTEN/SHIP/ at 72 h (top) and a graph showing the percentage of live (Ann V-PI) 
cells over time (bottom). Data are representative of n = 3 independent experiments. Error bars represent SD of the percentage of annexin V–propidium 
iodide (Ann V-PI) B cells for WT, bPTEN/, bSHIP/, and bPTEN/SHIP/ mice at each time point shown. (C) As in A, with the modification that cells 
were lysed at indicated time points and Western blotting performed to detect levels of pAkt (Ser 473), total Akt, pGSK3 (Ser 9), and MCL-1. Total ERK1/2 
levels were used as a loading control. Data are representative of n = 3 independent experiments. (D) Bim expression in freshly isolated splenic WT, bPTEN/, 
bSHIP/, or bPTEN/SHIP/ B cells was determined by immunoblotting with anti-Bim. Blots were stripped and reprobed with anti-actin antibodies as a 
loading control. Data are representative of n = 3 experiments.JEM VOL. 207, October 25, 2010 
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outside the follicles, but later invade both the white and red 
pulp when they progress to high-grade tumors (Morse et al., 
2002; Shin et al., 2004). Histological examination of spleen 
sections revealed that bPTEN/SHIP/ lymphomas were lo-
calized to follicles in this organ, often completely replacing 
normal structures, leaving virtually no small lymphocytes in 
the periarteriolar lymphoid sheaths (Fig. 1 D and Fig. 7 A). 
Moreover, splenic red pulp involvement was less prominent 
compared with reported cases of MZL but exhibited similar 
degrees of white pulp compression (Fig. 1 D; Morse et al., 2002; 
Shin et al., 2004).
Low-grade MZLs are typically comprised of uniform cells 
of medium size that are larger than, but cytologically very 
similar to, normal MZ B cells (Fredrickson et al., 1999; Morse 
et al., 2002). In contrast, high-grade MZLs reportedly retain 
Expression of PTEN and SHIP is reduced in human DLBCL
The histological and cytological features of lymphoid tissues 
of bPTEN/SHIP/ mice were consistent with the diagnosis 
of B cell lymphoma. To investigate the type of lymphomas 
that develop in bPTEN/SHIP/ animals, lymphomas were 
classified in accordance with the Bethesda proposals for mouse 
lymphoid neoplasms (Morse et al., 2002). Although the tumors 
of nearly all mice exhibited histological and cytological features 
most closely resembling those described for mouse splenic 
MZ lymphomas (MZL; Fig. 7, A and B; Morse et al., 2002), 
certain distinguishing characteristics suggested that bPTEN/
SHIP/ lymphomas were distinct from previously observed 
cases of MZL (Fredrickson et al., 1999; Morse et al., 2002; 
Shin et al., 2004). For example, MZLs are initially low-grade 
tumors restricted to the splenic MZ, which is located just 
Figure 7.  bPTEN/SHIP/ mice develop 
different B cell neoplasias. (A) Representa-
tive examples of B-NHL developed by bPTEN/
SHIP/ mice. (1) Normal spleen (10×): white 
pulp follicle filled with small lymphocytes 
surrounded by an MZ and red pulp. (2) MZL 
(10×): white pulp with a periarteriolar  
lymphoid sheath of small lymphocytes sur-
rounded by an expanse of uniform medium-
sized MZ B cells extending into the red pulp. 
(3) Centroblastic lymphoma (100×): white 
pulp is taken over by large blasts with dis-
persed chromatin and one or more nucleoli, 
often located near the nuclear membrane. 
One mitotic figure is seen near the center,  
and multiple apoptotic bodies are present.  
(4) Follicular lymphoma (100×): the white pulp 
is occupied by a heterogeneous population of 
smaller centrocytes with angulated and 
folded nuclei as well as larger centroblasts 
with more dispersed chromatin and peripheral 
nucleoli. (5) Plasmacytoma (100×): lymph 
node populated with plasmablasts with thick 
nuclear membranes and prominent nucleoli. 
Plasmacytic cells with relatively condensed 
chromatin and central nucleoli, and a promi-
nent mitotic figure are also present. (6) His-
tiocyte-associated DLBCL (100×): histiocytes 
with very large nuclei with reticular chroma-
tin and irregular nucleoli are present along 
with an abundance of foamy pink cytoplasm. 
One mitotic figure can be seen in the top 
right. The lymphoid population is comprised 
of centroblasts and several immunoblasts. 
Bars: (1 and 2) 500 µm; (3–6) 50 µm. (B) Clas-
sification of B-NHL displayed by bPTEN/
SHIP/ mice as determined by histological 
examination of splenic samples. CBL, centro-
blastic lymphoma; PCT, plasmacytoma; FL, 
follicular lymphoma. The chart represents  
15 different animals per group. (C) Relative 
levels of PTEN and SHIP mRNA transcripts in mouse B cell lymphoma determined by oligo-microarray. Values from 10–15 mice in each lymphoma group 
were tested against normal spleen by Mann-Whitney U test. The pink line shows the median in each group. CBL, centroblastic lymphoma; IBL, immuno-
blastic lymphoma; NOR, normal spleen. The mean Log2 normalized expression of PTEN and SHIP is plotted. P-values are indicated.2416 PTEN and SHIP regulate B cell transformation | Miletic et al.
classified into the following three groups based on PTEN, 
SHIP, and BCL6 expression: (1) the 25% of cases with the lowest 
levels of PTEN transcripts; (2) the 25% of cases with the low-
est levels of SHIP transcripts; and (3) the 25% of cases with 
the highest levels of BCL6 transcripts. These analyses revealed 
that patient samples with the lowest relative levels of PTEN 
(group 1) had SHIP transcripts significantly lower than the 
mean for all patients (Fig. 8 B, right, blue bar). Similarly, pa-
tient samples with low SHIP expression (group 2) had signifi-
cantly lower levels of PTEN transcripts than the mean for all 
patients (Fig. 8 B, left, orange bar). Patients with the highest 
levels of BCL6 transcripts (group 3), most of which report-
edly belong to the GC subset of DLBCL (Alizadeh et al., 2000), 
had levels of transcripts for both PTEN and SHIP that were 
significantly above the mean (Fig. 8 A), suggesting that the 
lymphomas of bPTEN/SHIP/ mice are probably not closely 
aligned to human GC-DLBCL. These results are consistent 
with coordinate tumor suppressor functions of these two phos-
phatases in B cells.
DISCUSSION
Cellular transformation in mammals is a complex and often 
multigenic process. Therefore, identifying and testing the genetic 
and epigenetic bases of particular malignancies has been chal-
lenging. In recent years, various studies have identified the 
tumor suppressor PTEN as a target in multiple tumor types 
and disease models. Studies of malignancies driven by loss-of-
function PTEN mutations and gain-of-function mutations   
in PI3K subunit genes have established the relevance of the 
PI3K pathway in promoting cancer (Yuan and Cantley, 2008). 
Surprisingly, a tumor suppressor role for INPP5D, the gene 
encoding SHIP, which also regulates PI3K signaling, has not 
been demonstrated (Rohrschneider et al., 2000). In this paper, 
we provide the first evidence that SHIP acts as a tumor sup-
pressor and that it acts in concert with PTEN to suppress   
B cell transformation.
Elevated PI3K signaling has recently been noted in selected 
B cell malignancies, namely MCL and DLBCL (Rudelius et al., 
2006; Uddin et al., 2006). MCL patients are highly responsive 
to rapamycin treatment to inactivate mTOR activity (Witzig 
their physical relationship to the MZ but take on features in-
distinguishable from those of centroblastic DLBCLs (CBLs; 
Fig. 7 A). Some cases of bPTEN/SHIP/ lymphomas exhibited 
mixed cell populations of centrocytes and centroblasts, which 
is consistent with a diagnosis of follicular B cell lymphoma 
(FL), whereas others were dominated by centroblasts as seen 
in CBL. Still others were characterized by sheets of plasma 
cells, which is consistent with a diagnosis of plasmacytoma 
(Fig. 7, A and B). It is noteworthy that both low- and high-
grade MZLs are almost always restricted to the spleen, whereas 
we consistently observed bPTEN/SHIP/ lymphoma infil-
trates in nonlymphoid tissues, including liver, lung, heart, and, 
occasionally, kidney (Fredrickson et al., 1999; Morse et al., 
2002). bPTEN/SHIP/ B cells did not predominate in the 
bone marrow, which occurs in B cell leukemia.
To corroborate these findings, we assessed expression of 
SHIP and PTEN transcripts in splenic samples from NFS.V 
congenic mice that spontaneously develop a spectrum of B lym-
phomas (Hartley et al., 2000; Shin et al., 2008). PTEN is down-
regulated in all lymphoma types, and SHIP is down-regulated 
in two types of DLBCL (CBL and IBL) and MZL but is sta-
tistically unchanged for FL. Collectively, these findings indi-
cate that bPTEN/SHIP/ mice develop lymphomas with 
overlapping similarities to several previously described subsets 
of mouse mature B cell lymphomas.
To examine the potential utility of the bPTEN/SHIP/ 
mouse as a model for human disease, levels of PTEN and/or 
SHIP transcripts in human B cell lymphomas were examined. 
The two most prevalent human B cell lymphomas, FL and   
DLBCL, represent >55% of all human mature B cell lymphomas 
(Evans and Hancock, 2003). Mutations that augment PI3K sig-
naling and inactivating PTEN mutations have recently been   
reported in some human DLBCL cases (Uddin et al., 2006;   
Abubaker et al., 2007; Lenz et al., 2008). Accordingly, existing pa-
tient microarray gene expression profiling data revealed a reduc-
tion in mean PTEN and SHIP expression in DLBCL compared 
with normal B cells (including naive, memory, and GC B cells) 
and the less aggressive FL (Alizadeh et al., 2000; Fig. 8 A).
To determine if subsets of DLBCL (previously distinguished 
based  on  differences  in  BCL6  expression; Alizadeh  et  al., 
2000) could be distinguished by levels of transcripts for PTEN 
and SHIP, data for 254 cases of DLBCL were examined and 
Figure 8.  Human DLBCL patients exhibit reduced PTEN 
and SHIP expression compared with FL patients. (A) cDNA 
expression analysis of human malignant B cell lymphoma sam-
ples from publicly available patient data (www.oncomine.org) 
comparing normal B cells, FL, and DLBCL showing mean (black 
lines) relative expression values for PTEN and SHIP cDNA. Each 
square represents an expression value for a single patient/sample. 
P-values comparing normal cells and DLBCL cells are indicated. 
(B) Mean Log2 normalized expression of PTEN and SHIP is plotted 
for the following patient groups: PTEN low (lowest 25% PTEN 
expression), SHIP low (lowest 25% SHIP expression), and BCL6 
high (highest 25% BCL6 expression), in comparison with mean 
values for all patients which were near 0. Analyses of other 
genes in the PTEN and SHIP low patient cohort confirmed that 
results were not a result of generally low cDNA signals in this 
cohort. *, P < 0.05; **, P < 0.005.JEM VOL. 207, October 25, 2010 
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that activation of PI3K effectors are enhanced after this stim-
ulus. This observation, taken with the collective results presented 
here, suggests that despite the hypoproliferative phenotype 
observed ex vivo, bPTEN/SHIP/ lymphoma progression is 
driven, at least partly, by signals through the antigen receptor 
but likely requires the contribution of additional receptor-
mediated signals.
In this regard, BAFF, which promotes B cell survival and 
supports BCR-dependent clonal expansion of normal B cells, 
is an attractive candidate. BAFF activates B cells to enter G1 
phase of the cell cycle marked by up-regulation of cyclin D, 
but cell cycle progression is halted before S phase without p27 
down-regulation and cyclin E up-regulation (Huang et al., 
2004). Notably, here we found that BAFF alone stimulated 
proliferation of bPTEN/SHIP/ B cells and that the combi-
nation of BAFF and anti-IgM stimuli synergistically enhanced 
proliferation. Indeed, in addition to its role in dampening BCR 
signaling, SHIP has been linked to suppression of BAFF-induced 
signals and acts in a BCR-dependent fashion to suppress signal-
ing via other receptors such as CXCR4 (Brauweiler et al., 2007; 
Crowley et al., 2009). Thus, it is possible that in the absence of 
PTEN, SHIP prevents transformation by regulating PIP3 levels 
induced by the BCR and other mitogenic signals and that in 
the absence of both phosphatases, the combination of un-
checked signals via multiple receptors promotes disease.
A role for BAFF in B cell malignancies has been suggested. 
Transgenic expression of either BAFF (when combined with 
TNF deficiency) or the related molecule APRIL results in B cell 
neoplasia in mice (Mackay et al., 1999; Planelles et al., 2004). 
Studies in humans implicate BAFF and/or APRIL in mature   
B cell lymphomas, multiple myeloma, B cell chronic lymphocytic 
leukemia, and Waldenstrom’s macroglobulinemia (Shivakumar 
and Ansell, 2006; Tangye et al., 2006). We did not find evidence 
of autocrine BAFF production by bPTEN/SHIP/ cells. 
Moreover, serum BAFF levels were not reduced, even in mice 
bearing a large tumor load (unpublished data), confirming 
that BAFF is not limiting in vivo. bPTEN/SHIP/ B cells 
acquire the ability to proliferate to BAFF, which typically only 
promotes survival. Although BAFF is absolutely required for 
late maturation of WT B cells, transfer of bPTEN/SHIP/  
B cells into BAFF/ recipients showed that its presence is 
not a strict requirement for B lymphoma progression. None-
theless, lymphoma progression appeared to be less aggressive 
in BAFF/ than in TCR-// recipients, suggesting that 
acute depletion of BAFF could deliver a therapeutic benefit 
in reducing tumor burden.
In summary, the bPTEN/SHIP/ model presented in 
this paper provides the first evidence that SHIP is a tumor 
suppressor. As such, this model will be useful for elucidating 
the specific roles of PTEN and SHIP in B cell neoplasia, as 
well as providing a novel platform for interrogating and ther-
apeutically manipulating the PI3K pathway in cancer. In a 
broader sense, the bPTEN/SHIP/ mice also provide a system 
with which to investigate B cell–intrinsic (e.g., the BCR) and 
microenvironmental (e.g., BAFF/APRIL) factors that pro-
mote lymphoma induction and progression.
and Kaufmann, 2006), and Akt activity is enhanced in many 
MCL lines that are dependent on PI3K for cell cycle progression 
and survival (Rudelius et al., 2006). Similarly, bPTEN/SHIP/ 
lymphoma cells are responsive to PI3K inhibitors and rapa-
mycin (unpublished data). Although the incidence of muta-
tions in PTEN in human cancers is second only to that of TP53 
(Stiles et al., 2004; Cully et al., 2006), we previously found 
that its loss in B cells does not cause transformation (Anzelon 
et al., 2003). In the case of DLBCL, reduced PTEN expression 
or predicted oncogenic PIK3CA mutations occurred in 37 and 
8% of cases, respectively. Both alterations were associated with 
poor overall survival (Abubaker et al., 2007). Consistent with 
these findings, PTEN expression was reduced but still present 
in primary MCL cases exhibiting elevated Akt activity (Rudelius 
et al., 2006), raising the possibility that SHIP expression or 
function may also be affected.
Importantly, SHIP has recently been identified as a miR-155 
target, causing reduced SHIP expression in a subset of DLBCL 
cases (Pedersen et al., 2009). This finding was confirmed in a 
miR-155 transgenic B lymphoma model (Costinean et al., 2009) 
and also reported in macrophages responding to inflamma-
tory stimuli (O’Connell et al., 2009). Intriguingly, these findings 
suggest that epigenetic down-regulation of SHIP expression by 
inflammation-induced miR-155 expression may promote trans-
formation of B cells with impaired PTEN function.
PTEN regulates PI(3,4,5)P3 levels in all resting and stimu-
lated cells. SHIP, in contrast, is expressed only in hematopoietic 
cells and depends on membrane recruitment via phospho-
tyrosine residues or SH3-based interactions for its activation 
(Leslie et al., 2008). In particular, upon recruitment to ITIM 
residues after coengagement with FcRIIB, SHIP mediates 
an inhibitory effect on BCR signaling. Thus, in the absence of 
PTEN, BCR-induced PI(3,4,5)P3 production likely remains 
dampened by SHIP. Accordingly, we postulate that disease in 
bPTEN/SHIP/ mice is promoted, at least in part, by tonic 
and/or antigen-mediated BCR signaling, which becomes lym-
phomagenic in the absence of both phosphatases. Indeed, BCR 
recognition of microbial or auto-antigens is thought to promote 
B-NHLs including MZL, CLL, and FL (Damle et al., 1999; 
Guyomard et al., 2003; Hervé et al., 2005). Clonal bPTEN/
SHIP/ lymphoma populations support a role for antigen-
mediated selection in lymphomagenesis. Moreover, height-
ened serum IgM and IgM deposits in bPTEN/SHIP/ heart 
and kidneys (unpublished data) are consistent with poly- or 
autoreactive antigen receptor signaling that may help drive 
lymphoma expansion in this animal model. Interestingly, how-
ever, bPTEN/SHIP/ lymphoma cells, which do not spon-
taneously proliferate, are also quite hypoproliferative in 
response to BCR stimulation in ex vivo cultures. It is possible 
that this reflects a refractory or tolerized state, perhaps caused 
by sustained antigen receptor ligation or tonic signaling. 
However, biochemistry studies indicate that Akt and other 
downstream effectors of the PI3K pathway are hyperactivated 
both basally and after various stimuli, including ligation of the 
antigen receptor. Thus, it is clear that B cells lacking PTEN 
and SHIP are not completely refractory to BCR ligation and 2418 PTEN and SHIP regulate B cell transformation | Miletic et al.
and M = A or C. PCR products generated represent V-DJH rearrangements 
having VH segments from either the distal J558 (VH1) family or the proximal 
7183 (VH5) family. Separation on a 1.5% agarose gel allowed for size-based 
separation of V-DJH products containing JH1 (1.3 kb), JH2 (0.95 kb), and JH3 
(0.4 kb) segments.
Adoptive transfers. B cells were purified from spleen cell as described in 
Assessment of IgH rearrangements. For transfers into TCR-/ recipients, 
107 WT  or  bPTEN/SHIP/  B  cells  were  injected  into  unmanipulated   
recipient animals via the tail vein. For transfers into BAFF/ recipients, 
BAFF/ mice were sublethally irradiated (5 Gy), followed by injection of   
107 WT or bPTEN/SHIP/ B cells via the tail vein. Presence of WT and   
bPTEN/SHIP/ was monitored by reduced expression of CD19 (as a result of   
CD19  heterozygosity)  and  later  by  lymphoma-like  phenotype  (B220/low 
CD5+CD11b+CD43+IgMlo) of bPTEN/SHIP/ B cells.
Cell culture, survival, and proliferation assays. B cells were purified 
from spleen cell suspensions according to standard procedures and cultured   
in  DME  medium  supplemented  with  10%  FCS,  pen/strep,  l-glutamine,   
Na-pyruvate, nonessential amino acids, and 2-mercaptoethanol (10% media). 
For proliferation assays, purified B cells were cultured at a concentration of   
5 × 104 cells/100 µl in 96-well round-bottom tissue culture plates at 37°C 
with 10 µg/ml anti-IgM F(ab')2 fragments (Jackson ImmunoResearch Labo-
ratories) in the presence or absence of 25 ng/ml BAFF (R&D Systems) or 
100 ng/ml APRIL (PeproTech), as indicated. Cells were pulsed with 1 µCi 
3H-thymidine at 48 h for an additional 12–16 h and then collected and scin-
tillation counted. The data are displayed as raw cpm values. All assays were 
conducted in triplicate. For survival assays, 200 µl of purified splenic B cells 
was plated in flat-bottom 96-well plates in triplicate at a concentration of   
5 × 105 cells/ml in 10% media. For assays involving BAFF blockade, cells 
were either cultured in media alone or in the presence of 10 ng/ml BAFF. 
Anti-BAFF IgG and control IgG (R&D Systems) were used at a concentra-
tion of 500 ng/ml. Every 24 h, cells were harvested and counted in triplicate 
using a Coulter counter (Beckman Coulter). Data are presented as averaged 
total cell numbers of three wells counted three times. Survival was also deter-
mined by flow cytometry using the AnnV-FITC Apoptosis Detection kit 
(BioVision Inc.) according to manufacturer’s instructions.
Immunoblotting. Purified B cells were stimulated with 10 µg/ml anti-IgM 
F(ab’)2 fragments in the presence or absence of 25 ng/ml BAFF for the indicated 
time points and lysed on ice with RIPA buffer (PBS, 1% NP-40, 0.5% deoxy-
cholate, 0.1% SDS, and 10 mM EDTA) supplemented with a protease inhibitor 
cocktail (Boehringer Mannheim), 10 mM NaF, 1 mM Na3VO4, and PMSF. Pro-
tein content of cleared lysates was measured using the BCA Protein Assay kit 
(Thermo Fisher Scientific), and equal protein amounts were resolved on 10% 
Bis-Tris Gels (Bio-Rad Laboratories or Invitrogen) followed by Western blotting 
for the indicated proteins. Antibodies raised against p27kip1, cyclin D3, actin,   
phospho-Akt (S473), total Akt, phospho-GSK3 (S9), total ERK1/2, and Bim 
were obtained from Cell Signaling Technology. Anti-MCL1 was purchased from 
Rockland Immunochemicals. Total anti-GSK3 was purchased from Millipore. 
Primary antibodies were detected using horseradish peroxidase–labeled donkey 
anti–rabbit (Jackson ImmunoResearch Laboratories) or anti–mouse antibodies 
(GE Healthcare). Immune complexes were detected by SuperSignal West Pico 
Detection chemiluminescence (Thermo Fisher Scientific).
cDNA microarray and analysis. Relative SHIP and PTEN transcript 
abundance in human samples was acquired from data provided by Alizadeh   
et al. (2000) via the Oncomine Cancer Profiling Database (www.oncomine 
.org). To obtain reported values, Alizadeh et al. (2000) normalized all raw array 
signals to the median chip expression signal (median expression = 1), fol-
lowed by Log2 transformation (Log2 values of 0 indicate mean expression 
across entire genome). For analysis of PTEN/SHIP co–down-regulation in 
human diseases, relative phosphatase expression among DLBCL patient sub-
sets was determined using microarray data for 254 patients from Rosenwald et al. 
(2002; available at http://llmpp.nih.gov/DLBCL/). Mean expression values 
of PTEN (probe U92436), SHIP (probe U57650), and BCL6 (probe U00115) 
MATERIALS AND METHODS
Generation of bPTEN/, bSHIP/, and bPTEN/SHIP/ mice. 
bPTEN/ mice were generated as previously described (Anzelon et al., 
2003). bSHIP/ mice were generated by crossing SHIPflox/flox (Karlsson   
et al., 2003) mice with Cd19Cre mice (Rickert et al., 1997) to generate   
B cell–specific deletion of SHIP. bPTEN/SHIP/ mice were generated by 
crossing PTENflox/flox (Lesche et al., 2002), SHIPflox/flox, and Cd19Cre+/ 
mice. All animals were heterozygous for Cd19Cre to achieve deletion of 
loxP-flanked exons while maintaining one CD19 allele. TCR-/ mice 
were purchased from The Jackson Laboratory. All animals were maintained 
in the animal facility of the Sanford-Burnham Medical Research Institute 
(SBMRI). All protocols were approved by the Institutional Animal Care and 
Use Committee at the SBMRI and were performed in accordance with in-
stitutional guidelines and regulations.
Mouse viability and disease analysis. To assess disease progression and animal 
viability/morbidity, cohorts of 15–20 animals per genotype were monitored over 
the course of 1 yr. Animals displaying signs of morbidity (lethargy, severe weight 
loss, hunched posture, ruffled fur, and slow movement) were considered morbid, 
euthanized, and scored as nonsurviving (note: if left alone, mice die within 2–3 d 
of development of the symptoms described). Hematology, including differentials 
and cytology, was performed by the University of California San Diego (UCSD) 
Animal Care Program Diagnostic Laboratory.
Histology. For paraffin-embedded sections, tissues were fixed immediately after 
harvest in 4% paraformaldehyde (Polysciences Inc.) for 24–48 h and stored in 
95% ethanol. Paraffin embedding, sectioning, and H&E staining were performed 
by the UCSD Cancer Center and by the SBMRI Histology Core facilities ac-
cording to standard protocols. Immunofluorescent staining of frozen tissue sec-
tions was performed as previously described (Anzelon et al., 2003) with indicated 
antibodies and reagents (see Flow cytometry and antibodies).
Flow cytometry and antibodies. Single cell suspensions were prepared, 
counted, and stained with antibodies according to standard procedures. First, 
cells were stained for 20 min at 4°C with biotinylated antibodies in flow cyto-
metry buffer (1% FBS and 0.1% azide in PBS), followed by incubation with 
a cocktail of antibodies conjugated to FITC, PE, peridinin chlorophyll pro-
tein complex–cyanine 5.5 (PerCP-Cy5.5.), PE-indotricarbocyanine (PE-Cy7), 
allophycocyanin (APC), or APC-Cy7. The following antibody conjugates were 
used (eBioscience): CD3 (145-2C11), IgM (II/41), IgD (11–26), CD5 (53–7.3), 
CD19 (ID3), B220 (RA3-6B2), CD11b (M1/70), CD43 (S7), CD21 (4E3), 
CD23 (B3B4), F4/80 (BM8), Gr1 (RB6-8C5), CD4 (GK1.5), CD8 (53–6.7), 
and CD11c (N418). Biotinylated reagents were detected with streptavidin 
(SAV)  conjugated  to  FITC,  PE, APC,  PerCP-Cy5.5  (BD),  and  PE-Cy7 
(eBioscience). All data were collected on a FACSCanto flow cytometer (BD) 
and analyzed using FlowJo software (Tree Star, Inc.). Data are displayed with 
logarithmic scale. Each plot represents analysis of 1–3 × 104 events.
Assessment of IgH rearrangements. B cells were purified from spleen 
cell suspensions by magnetic removal of cells stained with biotinylated antibodies 
against CD4 (GK1.5), CD3 (145-2C11), CD11c (N418), and Gr-1 (RB6-8C5; 
eBioscience)  followed  by  negative  selection  with  anti-biotin–conjugated 
MACS beads (Miltenyi Biotec). Purity of B cells routinely exceeded 85% as 
determined by flow cytometry. For Southern blot analysis, genomic DNA 
was digested with EcoRI, fractionated on a 1% agarose gel, and transferred to 
Zeta probe membrane (Bio-Rad Laboratories) followed by hybridization 
with oligonucleotide pJ11 probe. The probe was labeled by random hexamer 
priming using -[32P]dCTP.
For PCR analysis, DNA was isolated using phenol-chloroform extrac-
tion and was subjected to PCR using one of two degenerate 5 primers homolo-
gous to sequences from one of two different VH families (J558, 5-CGAGCT-
CTCCARCACAGCCTWCATGCATCTCARC-3; and 7183, 5-CGGT-
ACCAAGAASAMCCTGTWCCTGCAAATGASC-3)  and  a  common   
3 JH4 primer (5-TCCCTCAAATGAGCCTCCAAAGTCC-3). Degener-
ate nucleotide positions are coded as: R = A or G; W = A or T; S = C or G; JEM VOL. 207, October 25, 2010 
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were calculated in patient subgroups. Low and high expression groups were 
defined as the lowest or highest 25% for gene expression among all patients. 
P-values were calculated using a two-tailed unpaired Student’s t test assuming 
equal variance.
The relative transcript levels of SHIP and PTEN in mouse B cell lym-
phoma were determined by oligonucleotide arrays (available at GEO Data-
sets under accession no. GSE12157). The origins and characteristics of 
primary mouse B cell lineage lymphomas from NFS.V+ congenic and the 
techniques used for transcriptional profiling of those lymphomas were de-
tailed previously (Lee et al., 2006; Shin et al., 2008).
Online  supplemental  material. Fig. S1 shows that PTEN and SHIP 
are efficiently deleted in splenic bPTEN/SHIP/ B cells. Fig. S2 shows 
that  bPTEN/SHIP/  B  cells  have  clonal  Ig  repertoires  before  and   
after adoptive transfer into TCR-/ recipients in contrast with WT   
B cells which are polyclonal. Fig. S3 shows poor proliferation of bPTEN/
SHIP/ B cells in response to anti-IgM stimulation but robust prolif-
eration  of  bPTEN/SHIP/  B  cells  after  LPS  or  anti-CD40  stimula-
tion. Fig. S4 shows that bPTEN/SHIP/ B cells can survive and expand   
after adoptive transfer into BAFF/ recipients but do not produce auto-
crine BAFF. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20091962/DC1.
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